Advertisement

Applied Microbiology and Biotechnology

, Volume 103, Issue 19, pp 7931–7941 | Cite as

Preventative delivery of IL-35 by Lactococcus lactis ameliorates DSS-induced colitis in mice

  • Jianyong Wang
  • Miaomiao Tian
  • Wei Li
  • Fengqi HaoEmail author
Biotechnological products and process engineering
  • 109 Downloads

Abstract

Ulcerative colitis (UC) is one of the two major forms of inflammatory bowel disease (IBD) characterized by superficial mucosal inflammation, rectal bleeding, diarrhea, and abdominal pain. Anti-inflammatory and immunosuppressive drugs have been used in the therapy of human UC. Interleukin (IL)-35, which functions as an anti-inflammatory cytokine, has been shown to play a potential therapeutic role in a UC-like mouse colitis induced by dextran sodium sulfate (DSS). However, the contribution of IL-35 via oral administration to colitis prevention has not been determined. In order to explore its preventative potentiality, a dairy Lactococcus lactis NZ9000 strain was engineered to express murine IL-35 (NZ9000/IL-35), and this recombinant bacteria was applied to prevent and limit the development of DSS-induced mouse colitis. We found that oral administration of NZ9000/IL-35 induced the accumulation of IL-35 in the gut lumen of normal mice. When administrated preventatively, NZ9000/IL-35-gavaged mice exhibited decreased weight loss, DAI score, colon shortening as well as colitis-associated histopathological changes in colon, indicating that the oral administration of NZ9000/35 contributed to the suppression of DSS-induced colitis progression. Moreover, much less Th17 cells and higher level of Treg cells in lamina propria, as well as increased colon and serum levels of IL-10 with a concomitant reduced pro-inflammatory cytokines, IL-6, IL-17A, IFN-γ, and TNF-α were apparently regulated by NZ9000/IL-35 in colitis mice. Together, we put forward direct evidence pinpointing the effectiveness of NZ9000/IL-35 in preventing UC-like mouse colitis, implying a potential candidate of this recombinant Lactococcus lactis that prevent the progression of IBD.

Keywords

Lactococcus lactis Interleukin-35 Ulcerative colitis Inflammatory bowel disease Immunoregulation 

Notes

Acknowledgments

The authors thank Jian Hu for help with histopathological analysis.

Author contribution

Fengqi Hao conceived and designed study. Jianyong Wang and Miaomiao Tian performed research; Jianyong Wang and Wei Li analyzed data and wrote the manuscript; Fengqi Hao and Miaomiao Tian contributed to manuscript revision.

Funding information

This work was supported by grants from the Program of Science and Technology Development Plan of Jilin Province of China (Grant number, 20170101028JC).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References

  1. Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627–1640.  https://doi.org/10.1016/S0140-6736(07)60750-8 CrossRefGoogle Scholar
  2. Bermúdez-Humarán LG, Aubry C, Motta J-P, Deraison C, Steidler L, Vergnolle N, Chatel J-M, Langella P (2013) Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol 16:278–283.  https://doi.org/10.1016/j.mib.2013.06.002 CrossRefGoogle Scholar
  3. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon J, van Deventer SJH, Neirynck S, Peppelenbosch MP, Steidler L (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol 4:754–759.  https://doi.org/10.1016/j.cgh.2006.03.028 CrossRefGoogle Scholar
  4. Carvalho RDDO, do Carmo FLR, de Oliveira Junior A, Langella P, Chatel J-M, Bermúdez-Humarán LG, Azevedo V, de Azevedo MS (2017) Use of wild type or recombinant lactic acid bacteria as an alternative treatment for gastrointestinal inflammatory diseases: a focus on inflammatory bowel diseases and mucositis. Front Microbiol 8:800.  https://doi.org/10.3389/fmicb.2017.00800 CrossRefGoogle Scholar
  5. Chu H, Khosravi A, Kusumawardhani IP, Kwon AHK, Vasconcelos AC, Cunha LD, Mayer AE, Shen Y, Wu W-L, Kambal A, Targan SR, Xavier RJ, Ernst PB, Green DR, McGovern DPB, Virgin HW, Mazmanian SK (2016) Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science 352:1116–1120.  https://doi.org/10.1126/science.aad9948 CrossRefGoogle Scholar
  6. Ciaćma K, Więckiewicz J, Kędracka-Krok S, Kurtyka M, Stec M, Siedlar M, Baran J (2018) Secretion of tumoricidal human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by recombinant Lactococcus lactis: optimization of in vitro synthesis conditions. Microb Cell Factories 17:177–192.  https://doi.org/10.1186/s12934-018-1028-2 CrossRefGoogle Scholar
  7. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni H-T, Artis D, Turk MJ, Vignali DAA (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11:1093–1101.  https://doi.org/10.1038/ni.1952 CrossRefGoogle Scholar
  8. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DAA (2007) The inhibitory cytokine IL-35 contributes to regulatory T cell function. Nature 450:566–569.  https://doi.org/10.1038/nature06306 CrossRefGoogle Scholar
  9. Conrad K, Roggenbuck D, Laass MW (2014) Diagnosis and classification of ulcerative colitis. Autoimmun Rev 13:463–466.  https://doi.org/10.1016/j.autrev.2014.01.028 CrossRefGoogle Scholar
  10. Daniel C, Roussel Y, Kleerebezem M, Pot B (2011) Recombinant lactic acid bacteria as mucosal biotherapeutic agents. Trends Biotechnol 29:499–508.  https://doi.org/10.1016/j.tibtech.2011.05.002 CrossRefGoogle Scholar
  11. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138:583–594.  https://doi.org/10.1053/j.gastro.2009.10.037 CrossRefGoogle Scholar
  12. Friedrich M, Pohin M, Powrie F (2019) Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity 50:992–1006.  https://doi.org/10.1016/j.immuni.2019.03.017 CrossRefGoogle Scholar
  13. Friend DR (2005) New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev 57:247–265.  https://doi.org/10.1016/j.addr.2004.08.011 CrossRefGoogle Scholar
  14. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450.  https://doi.org/10.1038/nature12721 CrossRefGoogle Scholar
  15. Globig A-M, Hennecke N, Martin B, Seidl M, Ruf G, Hasselblatt P, Thimme R, Bengsch B (2014) Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease. Inflamm Bowel Dis 20:2321–2329.  https://doi.org/10.1097/MIB.0000000000000210 CrossRefGoogle Scholar
  16. Hisamatsu T, Kanai T, Mikami Y, Yoneno K, Matsuoka K, Hibi T (2013) Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther 137:283–297.  https://doi.org/10.1016/j.pharmthera.2012.10.008 CrossRefGoogle Scholar
  17. Holmén N, Lundgren A, Lundin S, Bergin A-M, Rudin A, Sjövall H, Öhman L (2006) Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 12:447–456.  https://doi.org/10.1097/00054725-200606000-00003 CrossRefGoogle Scholar
  18. Hovhannisyan Z, Treatman J, Littman DR, Mayer L (2011) Characterization of interleukin-17–producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140:957–965.  https://doi.org/10.1053/j.gastro.2010.12.002 CrossRefGoogle Scholar
  19. Jenke AC, Zilbauer M (2012) Epigenetics in inflammatory bowel disease. Curr Opin Gastroenterol 28:577–584.  https://doi.org/10.1097/MOG.0b013e328357336b CrossRefGoogle Scholar
  20. Jiang W, Su J, Zhang X, Cheng X, Zhou J, Shi R, Zhang H (2014) Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res 63:943–950.  https://doi.org/10.1007/s00011-014-0768-7 CrossRefGoogle Scholar
  21. Joan SSX, Pui-Fong J, Song AAL, Chang LY, Yusoff K, AbuBakar S, Rahim RA (2016) Oral vaccine of Lactococcus lactis harbouring pandemic H1N1 2009 haemagglutinin1 and nisP anchor fusion protein elevates anti-HA1 sIgA levels in mice. Biotechnol Lett 38:793–799.  https://doi.org/10.1007/s10529-016-2034-2 CrossRefGoogle Scholar
  22. Kanai T, Mikami Y, Sujino T, Hisamatsu T, Hibi T (2012) RORγt-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation. Mucosal Immunol 5:240–247.  https://doi.org/10.1038/mi.2012.6 CrossRefGoogle Scholar
  23. Kostic AD, Xavier RJ, Gevers D (2014) The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146:1489–1499.  https://doi.org/10.1053/j.gastro.2014.02.009 CrossRefGoogle Scholar
  24. Laass MW, Roggenbuck D, Conrad K (2014) Diagnosis and classification of Crohn’s disease. Autoimmun Rev 13:467–471.  https://doi.org/10.1016/j.autrev.2014.01.029 CrossRefGoogle Scholar
  25. Lautenschläger C, Schmidt C, Fischer D, Stallmach A (2014) Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev 71:58–76.  https://doi.org/10.1016/j.addr.2013.10.001 CrossRefGoogle Scholar
  26. Maddaloni M, Kochetkova I, Hoffman C, Pascual DW (2018) Delivery of IL-35 by Lactococcus lactis ameliorates collagen-induced arthritis in mice. Front Immunol 9:2691.  https://doi.org/10.3389/fimmu.2018.02691 CrossRefGoogle Scholar
  27. Mansour NM, Abdelaziz SA (2016) Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen. Microbiol Immunol 60:527–532.  https://doi.org/10.1111/1348-0421.12397 CrossRefGoogle Scholar
  28. Mao H, Gao W, Ma C, Sun J, Liu J, Shao Q, Song B, Qu X (2013) Human placental trophoblasts express the immunosuppressive cytokine IL-35. Hum Immunol 74:872–877.  https://doi.org/10.1016/j.humimm.2013.04.010 CrossRefGoogle Scholar
  29. Neurath MF (2014) Cytokines in inflammatory bowel disease. Nat Rev Immunol 14:329–342.  https://doi.org/10.1038/nri3661 CrossRefGoogle Scholar
  30. O’Flaherty S, Klaenhammer TR (2016) Multivalent chromosomal expression of the Clostridium botulinum serotype A neurotoxin heavy-chain antigen and the Bacillus anthracis protective antigen in lactobacillus acidophilus. Appl Environ Microbiol 82:6091–6101.  https://doi.org/10.1128/AEM.01533-16 CrossRefGoogle Scholar
  31. Scarpa M, Stylianou E (2012) Epigenetics: Concepts and relevance to IBD pathogenesis. Inflamm Bowel Dis 18:1982–1996.  https://doi.org/10.1002/ibd.22934 CrossRefGoogle Scholar
  32. Sekiya T, Kashiwagi I, Inoue N, Morita R, Hori S, Waldmann H, Rudensky AY, Ichinose H, Metzger D, Chambon P, Yoshimura A (2011) The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells. Nat Commun 2:269.  https://doi.org/10.1038/ncomms1272 CrossRefGoogle Scholar
  33. Shi S, Yang W, Yang G, Cong Y, Huang H, Wang Q, Cai R, Ye L, Hu J, Zhou J, Wang C, Li Y (2014) Immunoprotection against influenza virus H9N2 by the oral administration of recombinant Lactobacillus plantarumNC8 expressing hemagglutinin in BALB/c mice. Virology 464–465:166–176.  https://doi.org/10.1016/j.virol.2014.07.011 CrossRefGoogle Scholar
  34. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352–1355.  https://doi.org/10.1126/science.289.5483.1352 CrossRefGoogle Scholar
  35. Teymouri M, Pirro M, Fallarino F, Gargaro M, Sahebkar A (2018) IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. Int J Cancer 143:2105–2115.  https://doi.org/10.1002/ijc.31382 CrossRefGoogle Scholar
  36. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, Tannapfel A, Fontenot JD, Ramsdell F, Powrie F (2006) Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 177:5852–5860.  https://doi.org/10.4049/jimmunol.177.9.5852 CrossRefGoogle Scholar
  37. Van Hoang V, Ochi T, Kurata K, Arita Y, Ogasahara Y, Enomoto K (2018) Nisin-induced expression of recombinant T cell epitopes of major Japanese cedar pollen allergens in Lactococcus lactis. Appl Microbiol Biotechnol 102:261–268.  https://doi.org/10.1007/s00253-017-8579-8 CrossRefGoogle Scholar
  38. Wang Y, Mao Y, Zhang J, Shi G, Cheng L, Lin Y, Li Y, Zhang X, Zhang Y, Chen X, Deng J, Su X, Dai L, Yang Y, Zhang S, Yu D, Wei Y, Deng H (2018) IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells. J Cell Mol Med 22:1014–1025.  https://doi.org/10.1111/jcmm.13428 Google Scholar
  39. Watson AJM, Hart AR (2011) Environmental risk factors for inflammatory bowel disease: microbes, diet, and the appendix. Gastroenterology 141:768–770.  https://doi.org/10.1053/j.gastro.2011.06.013 CrossRefGoogle Scholar
  40. Wells JM, Mercenier A (2008) Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6:349–362.  https://doi.org/10.1038/nrmicro1840 CrossRefGoogle Scholar
  41. Wirtz S, Billmeier U, Mchedlidze T, Blumberg RS, Neurath MF (2011) Interleukin-35 mediates mucosal immune responses that protect against T-cell–dependent colitis. Gastroenterology 141:1875–1886.  https://doi.org/10.1053/j.gastro.2011.07.040 CrossRefGoogle Scholar
  42. Wirtz S, Neufert C, Weigmann B, Neurath MF (2007) Chemically induced mouse models of intestinal inflammation. Nat Protoc 2:541–546.  https://doi.org/10.1038/nprot.2007.41 CrossRefGoogle Scholar
  43. Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF (2017) Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc 12:1295–1309.  https://doi.org/10.1038/nprot.2017.044 CrossRefGoogle Scholar
  44. Won HY, Jang EJ, Lee K, Oh S, Kim HK, Woo HA, Kang SW, Yu D-Y, Rhee S-G, Hwang ES (2013) Ablation of peroxiredoxin II attenuates experimental colitis by increasing FoxO1-induced Foxp3+ regulatory T cells. J Immunol 191:4029–4037.  https://doi.org/10.4049/jimmunol.1203247 CrossRefGoogle Scholar
  45. Wu GD, Bushmanc FD, Lewis JD (2013) Diet, the human gut microbiota, and IBD. Anaerobe 24:117–120.  https://doi.org/10.1016/j.anaerobe.2013.03.011 CrossRefGoogle Scholar
  46. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427–434.  https://doi.org/10.1038/nature06005 CrossRefGoogle Scholar
  47. Zeng Z, Yu R, Zuo F, Zhang B, Ma H, Chen S (2017) Recombinant Lactococcus lactis expressing bioactive exendin-4 to promote insulin secretion and beta-cell proliferation in vitro. Appl Microbiol Biotechnol 101:7177–7186.  https://doi.org/10.1007/s00253-017-8410-6 CrossRefGoogle Scholar
  48. Zhang B, Li A, Zuo F, Yu R, Zeng Z, Ma H, Chen S (2016) Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells. Microb Cell Factories 15:102–112.  https://doi.org/10.1186/s12934-016-0506-7 CrossRefGoogle Scholar
  49. Zhang B, Liu Y, Lan X, Xu X, Zhang X, Li X, Zhao Y, Li G, Du C, Lu S, Wang H (2018) Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice. J Transl Med 16:71.  https://doi.org/10.1186/s12967-018-1441-7 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.School of Life Science and TechnologyChangchun University of Science and TechnologyJilinPeople’s Republic of China
  2. 2.Key Laboratory of Molecular Epigenetics of the Ministry of EducationNortheast Normal UniversityJilinPeople’s Republic of China

Personalised recommendations